Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Back to Small Cell Carcinoma

Small Cell Carcinoma — NIH Grants & Funding

Active and recent NIH-funded research on Small Cell Carcinoma. Data from NIH RePORTER, last 36 months.

MONDO:0000402

NIH-funded research on Small Cell Carcinoma

active grants

institutions

researchers

new in last 12 mo.

$32.1M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(23)

Basic ScienceZIACompleted

Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies

Thomas, Anish·DIVISION OF BASIC SCIENCES - NCI

$4,075,119 (FY2025)

Small Cell Carcinoma — NIH Grants & Funding

Basic Science(23)

Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies

Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies

Cellular plasticity gives rise to phenotypic equilibrium in small cell lung carcinoma

Mechanisms of Arginine Deprivation in Small Cell Lung Cancer

Understanding the molecular mechanism of a protein-recycling complex in small cell lung cancer treatment resistance.

Uncovering Epigenetic and Transcriptional Drivers of Neuroendocrine Plasticity at Single-Cell Level in Patients with Small Cell Lung Cancer Transformation

Targeting the immunologic vulnerabilities of small cell lung carcinoma

Phenotype Heterogeneity and Dynamics in SCLC

Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors

Molecular mechanisms of SCLC initiation and detection in mice and humans

Translational(11)

Novel therapeutic development for small cell lung cancer

Targeting polo-like kinase for therapy of small cell lung cancer

Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response

Translating Autoantibodies Into Chimeric Antigen Receptor-T cell Therapy for Small Cell Lung Cancer

DNA damaging therapy and immune response in small cell lung cancer subtypes

Developing an Effective BET bromodomain inhibitor Drug Combo to Target SCLC

Employing CRISPR inactivation screening and in vivo models towards improving treatments for SCLC

Targeting replication stress signaling to overcome immune evasion in small cell lung cancer

Bioinformatic-Chemical Approach to Credential Molecular Targets to Combat Rapid Chemo-Radiation Resistance in SCLC

Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression

Clinical(2)

Targeting alternative splicing for TCR discovery in small cell carcinomas

Using patient-derived models to understand drug responses in SCLC

Epi / Nat. History(1)

Targeting BCAT1 and branched-chain amino acid metabolism for the detection and prevention of SCLC

Gene/Cell Therapy(2)

Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer

Exploiting POU2F3 addiction in the tuft cell variant of small cell lung cancer

Biomarker / Dx(4)

Predictive biomarker of BET bromodomain inhibitor in Small cell lung cancer

Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung Cancer

Phenotype Interactions in SCLC Development and Detection

Tumor-specific autoantibodies for SCLC early detection

Other(2)

Novel approach to attenuate small cell lung cancer growth and metastasis

The Risk of Developing Alzheimer’s Disease and Related Dementias Associated with Hypertension, Diabetes, and Drug Therapies for Cancer: Up to 30-year Follow-up for Older Medicare Beneficiaries